

Efficacy and safety of the probiotic *Saccharomyces boulardii* for the prevention and therapy of gastrointestinal disorders

Theodoros Kelesidis and Charalabos Pothoulakis

Abstract: Several clinical trials and experimental studies strongly suggest a place for *Saccharomyces boulardii* as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. *S. boulardii* mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of *S. boulardii* and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of *S. boulardii* as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.

Keywords: efficacy, gastrointestinal disorders, probiotic, *Saccharomyces boulardii*, safety

Introduction

There is increasing evidence that the gastrointestinal microflora is a major regulator of the immune system, not only in the gut, but also in other organs [Gareau *et al.* 2010]. The nonpathogenic yeast *Saccharomyces boulardii* has been prescribed in the past 30 years for prophylaxis and treatment of diarrheal diseases caused by bacteria. Importantly, *S. boulardii* has demonstrated clinical and experimental effectiveness in gastrointestinal diseases with a predominant inflammatory component, indicating that this probiotic might interfere with cellular signaling pathways common in many inflammatory conditions. The goal of this study is to review the clinical evidence for efficacy and safety of *S. boulardii* in the prevention and treatment of gastrointestinal disorders with diverse etiology.

Saccharomyces boulardii as a probiotic

An increasing number of potential health benefits are being attributed to probiotic treatments [Gareau *et al.* 2010; Szajewska *et al.* 2006]. However, only a limited number have been confirmed in well-designed and conducted randomized controlled trials (RCTs) and even less in the pediatric population. *S. boulardii* is a live yeast used extensively as a probiotic and often

marketed as a dietary supplement [McFarland, 2010]. Several mechanisms of action have been identified directed against the host as well as pathogenic microorganisms and include regulation of intestinal microbial homeostasis, interference with the ability of pathogens to colonize and infect the mucosa, modulation of local and systemic immune responses, stabilization of the gastrointestinal barrier function and induction of enzymatic activity favoring absorption and nutrition (Tables 1 and 2) [Czerucka *et al.* 2007; Im and Pothoulakis, 2010; Pothoulakis, 2009].

The multiple prophylactic and therapeutic effects of this probiotic yeast in inflammatory gastrointestinal diseases underline the efficacy of *S. boulardii* in enteric diseases. This efficacy in the prevention and the treatment of acute and chronic gastrointestinal diseases is determined by many factors (Table 3) and has been assessed in several clinical trials (Table 4).

Factors that determine efficacy of *Saccharomyces boulardii* as a probiotic

The efficacy of *S. boulardii* as a probiotic involves many factors, including the intrinsic properties of the yeast (Table 3), its pharmacokinetics (Table 3),

Ther Adv Gastroenterol

(2012) 5(2) 111–125

DOI: 10.1177/

1756283X11428502

© The Author(s), 2011.

Reprints and permissions:

[http://www.sagepub.co.uk/](http://www.sagepub.co.uk/journalsPermissions.nav)

[journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Correspondence to:

Charalabos Pothoulakis, MD

Inflammatory Bowel Disease Center, Div. of Digestive Diseases, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
cpothoulakis@mednet.ucla.edu

Theodoros Kelesidis, MD

Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Table 1. Mechanisms of action of *Saccharomyces boulardii*.

Action of <i>Saccharomyces boulardii</i>	References
Luminal action	
A) Antimicrobial activity	
1) Inhibition of growth of bacteria and parasites	[Chen <i>et al.</i> 2006; Czerucka <i>et al.</i> 1994; Czerucka and Rampal, 2002; Dahan <i>et al.</i> 2003; Dalmaso <i>et al.</i> 2006a; Gedek, 1999a; Rigother <i>et al.</i> 1994; Rodrigues <i>et al.</i> 1996; Mumy <i>et al.</i> 2008; Wu <i>et al.</i> 2008]
2) Reduction of gut translocation of pathogens	[Herek <i>et al.</i> 2004; Geyik <i>et al.</i> 2006]
3) Neutralization of bacterial virulence factors	[Buts <i>et al.</i> 1994; Jahn <i>et al.</i> 1996]
4) Suppression of host cell adherence that interferes with bacterial colonization	[Czerucka <i>et al.</i> 2000; Rodrigues <i>et al.</i> 1996; Wu <i>et al.</i> 2008]
B) Antitoxin effects	
1) Inhibition of toxin receptor binding sites	[Buts <i>et al.</i> 2006; Castagliuolo <i>et al.</i> 1996, 1999; Czerucka <i>et al.</i> 2000; Tasteyre <i>et al.</i> 2002; Wu <i>et al.</i> 2008]
2) Stimulation of antibody production against <i>Clostridium difficile</i> toxin A	[Brandao <i>et al.</i> 1998; Qamar <i>et al.</i> 2001]
3) Direct proteolysis of the pathogenic toxins/Secretion of enzymatic proteins	[Buts <i>et al.</i> 2006; Castagliuolo <i>et al.</i> 1996; Pothoulakis <i>et al.</i> 1993]
a) Produces a serine protease that cleaves <i>C. difficile</i> toxin A	[Pothoulakis <i>et al.</i> 1993]
b) Produces 63 kDa phosphatase that destroys the endotoxin of pathogenic <i>Escherichia coli</i>	[Buts <i>et al.</i> 2006; Castagliuolo <i>et al.</i> 1996]
c) Produces a 120 kDa protein that reduces the effects of cholera toxin	[Czerucka <i>et al.</i> 1994]
C) Cross-talk with normal microbiota	
When <i>S. boulardii</i> is given to antibiotic-exposed mice or patients with diarrhea, normal microbiota is re-established rapidly	[Buts <i>et al.</i> 1986, 1999, 2006; Buts, 2009; Swidsinski <i>et al.</i> 2008]
Trophic action on the intestinal mucosa	
1) Reduces the number of infected cells and stimulates the growth and differentiation of intestinal cells in response to trophic factors	[Barc <i>et al.</i> 2008; Swidsinski <i>et al.</i> 2008]
2) Prevents apoptosis and synthesis of TNF α	[Czerucka <i>et al.</i> 2000; Dahan <i>et al.</i> 2003; Dalmaso <i>et al.</i> 2006b]
3) Reduces mucositis	[Buts <i>et al.</i> 1986, 1999, 2006; Buts, 2009]
4) Restores fluid transport pathways	[Schneider <i>et al.</i> 2005]
5) Stimulates protein and energy production and restores metabolic activities in colonic epithelial cells	[Czerucka <i>et al.</i> 2007; Szajewska <i>et al.</i> 2007; Zanello <i>et al.</i> 2009]
6) Secretes mitogenic factors that enhance cell restitution	[Canonici <i>et al.</i> 2011]
7) Enhances release of brush-border membrane enzymes	[Buts <i>et al.</i> 1998, 2002; Schneider <i>et al.</i> 2005]
8) Stimulates the production of glycoproteins in the brush border	[Buts <i>et al.</i> 1990]
9) Stimulates production of intestinal polyamines	[Buts <i>et al.</i> 1986, 1994, 1999, 2002; Jahn <i>et al.</i> 1996; Schneider <i>et al.</i> 2005]
10) Restores normal levels of colonic short chain fatty acids (SCFAs)	[Buts <i>et al.</i> 1994; Sezer <i>et al.</i> 2009; Breves <i>et al.</i> 2000]
11) Stabilizes gastrointestinal barrier function and strengthens enterocyte tight junctions	[Czerucka <i>et al.</i> 2007; Dahan <i>et al.</i> 2003; Szajewska <i>et al.</i> 2007; Wu <i>et al.</i> 2008; Zanello <i>et al.</i> 2009]
12) Reduces crypt hyperplasia and cell damage in colitis models	[Wu <i>et al.</i> 2008]
13) Decreases intestinal permeability in Crohn's disease patients	[Garcia <i>et al.</i> 2008]

Action of <i>Saccharomyces boulardii</i>	References
Regulation of immune response	
A) By acting as an immune stimulant	
<i>S. boulardii</i> effects on innate immunity	
1) Triggers activation of complement and migration of monocytes and granulocytes	[Caetano <i>et al.</i> 1986]
2) Enhances the number of K�pffer cells in germfree mice	[Rodrigues <i>et al.</i> 2000]
<i>S. boulardii</i> effects on adaptive immunity	
1) Enhances the mucosal immune response and secretory IgA intestinal levels	[Buts <i>et al.</i> 1990; Czerucka <i>et al.</i> 2007; Generoso <i>et al.</i> 2011; Szajewska <i>et al.</i> 2007; Zanello <i>et al.</i> 2009]
2) Enhances systemic immune response and levels of serum IgG to <i>C. difficile</i> toxins A and B.	[Czerucka <i>et al.</i> 2007; Qamar <i>et al.</i> 2001]
3) Contributes to earlier production of IFN-� and IL-12	[Rodrigues <i>et al.</i> 2000; Thomas <i>et al.</i> 2009]
4) Stimulates regulatory T cells	[Jahn <i>et al.</i> 1996]
5) Inhibits dendritic cell-induced activation of T cells	[Dalmaso <i>et al.</i> 2006a]
6) Modifies migration of lymphocytes in a chronic inflammatory bowel disease model	[Dalmaso <i>et al.</i> 2006a]
7) Modifies lymphocyte adherence to endothelial cells, improves cell rolling and adhesion	[Dalmaso <i>et al.</i> 2006a]
B) By reducing pro-inflammatory responses and promoting mucosal anti-inflammatory signaling effects	
1) Decreases expression of pro-inflammatory cytokines (IL-8, IL-6, IL-1�, TNF-� and IFN-�)	[Dahan <i>et al.</i> 2003; Dalmaso <i>et al.</i> 2006a, 2006b; Mummy <i>et al.</i> 2008; Sougioultzis <i>et al.</i> 2006]
2) Increases expression of the anti-inflammatory cytokine IL-10	[Generoso <i>et al.</i> 2011]
3) Interferes with NF-�B-mediated signal transduction pathways, in immune and colonic epithelial cells	[Buts, 2009; Dahan <i>et al.</i> 2003; Mummy <i>et al.</i> 2008; Pant <i>et al.</i> 2007; Sougioultzis <i>et al.</i> 2006]
4) Blocks activation of ERK1/2 and MAP kinases	[Chen <i>et al.</i> 2006; Kyne <i>et al.</i> 2001; Mummy <i>et al.</i> 2008; Sougioultzis <i>et al.</i> 2006]
5) Decreases NO and inhibits production of inducible NOS	[Girard <i>et al.</i> 2005]
6) Modulates T cell migratory behavior and increases trapping of T helper cells into mesenteric lymph nodes	[Dalmaso <i>et al.</i> 2006a; Fidan <i>et al.</i> 2009; Sougioultzis <i>et al.</i> 2006; Thomas <i>et al.</i> 2009]
7) Stimulates production of anti-inflammatory molecules in human colonocytes such as PPAR-�	[Chen <i>et al.</i> 2006; Lee <i>et al.</i> 2005, 2009; Mummy <i>et al.</i> 2008]
ERK, extracellular signal-regulated kinase; IL, interleukin; INF-�, interferon gamma; IgA, Immunoglobulin A; IGF, insulin growth factor; MAP, mitogen-activated protein; NF-�B, nuclear factor kappa B; NO, nitric oxide; NOS, nitric oxide synthase; PPAR-�, peroxisome proliferator-activated receptor-gamma; TNF�: tumor necrosis factor alpha	

product to product variation, and stability, number of strains used in the probiotic preparation and dose of the probiotic used.

There are many different *Saccharomyces* products commercially available sold as probiotics and *S. boulardii* is usually available in capsules of either lyophilized or heat-dried preparations [McFarland, 2010]. The choice of a high-quality probiotic product is one of the most important factors that determine efficacy of the probiotic. The quality of these products from different sources may vary and many of the commercially available products may lack regulated quality control programs [Marcobal *et al.* 2008; Martins

et al. 2005; Masco *et al.* 2005; Weese, 2003]. Even if the label states it contains *S. boulardii*, a variation in efficacy may occur due to lower than stated dose or inaccurate strain composition [Martins *et al.* 2009]. Selecting high-quality probiotic products can be difficult without access to specific quality control assays for commercially available probiotic products. Selecting products from companies that sponsor original clinical trials may indicate a higher degree of commitment to high-quality products [McFarland, 2010].

The stability of the probiotic product may significantly affect its potency over time. Lyophilized products are stable at room temperature, have the

Table 2. Mechanisms of action of *Saccharomyces boulardii* in specific infections.

Action of <i>Saccharomyces boulardii</i>	References
<i>Clostridium difficile</i> infection	
1) Inhibits toxin A-mediated diarrhea, intestinal inflammation and histological damage by reducing toxin A-receptor binding	[Castagliuolo <i>et al.</i> 1996; Pothoulakis <i>et al.</i> 1993]
2) Releases a protease that cleaves <i>C. difficile</i> toxins and toxin intestinal receptors	[Castagliuolo <i>et al.</i> 1996; Pothoulakis <i>et al.</i> 1993]
3) Stimulates specific intestinal antitoxin A immunoglobulin levels	[Castagliuolo <i>et al.</i> 1996, 1999; Pothoulakis <i>et al.</i> 1993]
4) Inhibits IL-8 production and activation of the MAP kinases Erk1/2 and JNK/SAPK induced by <i>C. difficile</i> toxin A in human colonocytes	[Chen <i>et al.</i> 2006; Qamar <i>et al.</i> 2001]
5) Significantly fewer animals challenged with <i>C. difficile</i> died if given <i>S. boulardii</i> compared with controls	[Castex <i>et al.</i> 1990; Elmer and Corthier, 1991; Rodrigues <i>et al.</i> 1996; Toothaker and Elmer, 1984]
<i>Helicobacter pylori</i> infection	
Alters the structure of <i>H. pylori</i>	[Vandenplas <i>et al.</i> 2009]
<i>Vibrio cholerae</i> infection	
1) Inhibits the effect of <i>V. cholerae</i> toxin and hydroelectrolytic secretions by reducing cAMP activity	[Vidon <i>et al.</i> 1986; Czerucka <i>et al.</i> 1994]
2) <i>S. boulardii</i> and the mammalian CT receptors could be structurally and functionally similar and the yeast binds CT	[Brandao <i>et al.</i> 1998; Czerucka <i>et al.</i> 1994]
Amebic dysentery	
1) Reduces the number of red cells adhering to amoebae	[Rigothier <i>et al.</i> 1994]
2) Decreases the number of amoebae bearing red cells	[Rigothier <i>et al.</i> 1994]
Infection with EHEC	
1) <i>S. boulardii</i> modifies host signaling such as NF- κ B-associated pathways activated by bacterial invasion with EHEC	[Dahan <i>et al.</i> 2002, 2003]
2) Addition to T84 colonocyte monolayers diminishes MLC phosphorylation and decreases transepithelial resistance in response to EHEC	[Dahan <i>et al.</i> 2002, 2003]
Infection with EPEC	
1) Modifies EPEC infection and acts as a receptor decoy for EPEC	[Buts <i>et al.</i> 2006; Canil <i>et al.</i> 1993; Czerucka <i>et al.</i> 2000; Gedek, 1999b]
2) Reduces the number of intracellular EPEC	[Buts <i>et al.</i> 2006; Canil <i>et al.</i> 1993; Czerucka <i>et al.</i> 2000; Gedek, 1999b]
3) Blocks transepithelial resistance and permeability changes, reverses impaired ZO-1 distribution and delays apoptosis of epithelial cells in response to EPEC	[Buts <i>et al.</i> 2006; Canil <i>et al.</i> 1993; Czerucka <i>et al.</i> 2000; Gedek, 1999b]
4) Dephosphorylates LPS from <i>Escherichia coli</i> strain O55B5	[Buts <i>et al.</i> 2006; Canil <i>et al.</i> 1993; Czerucka <i>et al.</i> 2000; Gedek, 1999b]
CT, cholera toxin; EHEC, enterohemorrhagic <i>E. coli</i> ; EPEC, enteropathogenic <i>E. coli</i> ; ERK, extracellular signal-regulated kinase; LPS, lipopolysaccharide; MAP, mitogen-activated protein; MLC, myosin light chain; NF- κ B, nuclear factor kappa B; ZO-1, zonula occludens 1	

Table 3. Properties of *Saccharomyces boulardii* that can determine the efficacy of *S. boulardii*.

Properties of <i>Saccharomyces boulardii</i>	References
1) Survives passage to its target organ (most commonly the colon): although much of the oral dose is destroyed (usually stool levels are 100–1000 times lower than the oral dose), surviving oral doses have been found to be effective (usually at levels over 10 ⁸ organisms/gram stool)	[Gorbach, 2000]
2) Survives at body temperature (37°C): unique advantage of being one of the few yeasts that do best at human body temperatures	[Graff <i>et al.</i> 2008b]
3) In lyophilized form, <i>S. boulardii</i> survives gastric acid and bile	[Graff <i>et al.</i> 2008b]
4) As is the case with all yeasts, <i>S. boulardii</i> is naturally resistant to antibiotics	[Graff <i>et al.</i> 2008b]
5) <i>S. boulardii</i> is resistant to proteolysis	[Buts, 2009]
6) <i>S. boulardii</i> exists in the competitive milieu of the intestinal tract	[Buts, 2009]
7) <i>S. boulardii</i> levels are higher in patients with disturbed intestinal microbiota (due to antibiotic exposure) compared to patients without antibiotic exposure	[Klein <i>et al.</i> 1993]
8) When given orally, achieves steady-state concentrations within three days and is cleared within 3–5 days after it is discontinued	[Blehaut <i>et al.</i> 1989; Elmer <i>et al.</i> 1999b]
9) Some types of fiber (psyllium) increased <i>S. boulardii</i> levels by 22%, while other types of fiber (pectin) showed no effect.	[Elmer <i>et al.</i> 1999a]

Table 4. Clinical efficacy of *Saccharomyces boulardii* in acute and chronic diseases.

Acute diseases
1) Antibiotic-associated diarrhea
2) <i>Clostridium difficile</i> infection
3) Acute diarrhea
4) Persistent diarrhea
5) Enteral nutrition-related diarrhea
6) Traveler's diarrhea
7) <i>Helicobacter pylori</i> infection
Chronic diseases
1) Crohn's disease
2) Ulcerative colitis
3) Irritable bowel syndrome
4) Parasitic infections <ul style="list-style-type: none"> a) <i>Amebic colitis</i> b) <i>Giardiasis</i> c) <i>Blastocystis hominis</i>
5) Human immunodeficiency virus (HIV)-related diarrhea

advantage of portability and maintain high viability counts over prolonged periods [Graff *et al.* 2008a]. Heat-dried preparations must be refrigerated and may not be stable at room temperature [McFarland, 2010]. A study of *S. boulardii* products found a lyophilized product outperformed three heat-killed *S. boulardii* preparations in terms of pharmacokinetics and higher number of viable cells [Schwenzer, 1998].

All of the RCTs using *S. boulardii* have utilized a single-strain preparation. Although mixtures of probiotics containing *S. boulardii* are available on the market, no RCTs have been performed showing that these mixtures are superior to the single-strain preparations. Preclinical studies in animal models have found promising results in probiotic mixtures containing *S. boulardii* [Bisson *et al.* 2010]. However, possible antagonism between the different probiotics may attenuate the therapeutic responses of the probiotic strains [Kajander *et al.* 2008].

Finally, the dose of *S. boulardii* used can also affect the efficacy of this probiotic [McFarland, 2010]. Different doses of *S. boulardii* used in different studies may explain some of the discrepancies in the efficacy and outcomes between these studies. Unfortunately, the dose of *S. boulardii* used is not reported consistently in all studies while in other studies the dose used is reported heterogeneously between different studies (e.g. number of organisms per 100 ml or number of organisms per day or colony forming units [cfu] per day or grams per day) [McFarland, 2010]. This heterogeneity limits meta-analyses and further analysis of the effect of dose of *S. boulardii* on its efficacy.

Clinical efficacy of *Saccharomyces boulardii* as a probiotic in acute gastrointestinal conditions

S. boulardii has been tested for clinical efficacy in several types of acute gastrointestinal conditions, including antibiotic-associated diarrhea (AAD), *Clostridium difficile* infection (CDI), acute

diarrhea, enteral nutrition-related diarrhea, traveler's diarrhea and *Helicobacter pylori* infection.

Antibiotic-associated diarrhea

AAD is defined as otherwise unexplained diarrhea that occurs in association with the administration of antibiotics [Bartlett, 2002]. Measures to prevent AAD include the use of probiotics. Of the 10 controlled trials in adults using *S. boulardii* for the prevention of AAD, 8 (80%) showed significant efficacy for the prevention of AAD [McFarland, 2010]. The protective effect of *S. boulardii* and the significant relative reduction in AAD compared with controls ranged between 7.4% and 25% [McFarland, 2010]. Other studies failed to demonstrate a significant protective effect of *S. boulardii* and this may be secondary to short or no follow-up after antibiotic exposure [McFarland, 2009]. Two RCTs have assessed the ability of *S. boulardii* to prevent AAD in children and the relative significant increase in prevention of AAD in the *S. boulardii* group compared with controls ranged between 7.6% and 30.1% [Can *et al.* 2006; Kotowska *et al.* 2005].

A recent meta-analysis of the 10 randomized, controlled trials in adults found that *S. boulardii* was significantly protective for AAD with a pooled relative risk (RR) of 0.47 (95% confidence interval [CI] 0.35–0.63, $p < 0.001$) [McFarland, 2010]. Finally, in another meta-analysis from five trials involving 1076 subjects, a significantly protective effect of *S. boulardii* was found (pooled RR = 0.43, 95% CI 0.23–0.78) [Szajewska and Mrukowicz, 2005]. However, although many meta-analyses have concluded that probiotics are effective for preventing AAD [McFarland, 2009], most probiotic meta-analyses have focused on one type of disease indication (e.g. antibiotic associated diarrhea) with a variety of probiotic strains. Thus, we summarized data from meta-analyses that are focused only on the use of *S. boulardii* in preventing AAD and conclude that this probiotic is efficacious for this indication.

Clostridium difficile infection

Probiotics represent a promising approach as an adjunctive therapy for CDI. A meta-analysis of six RCTs of different probiotics, including *S. boulardii* showed that probiotics had a significant efficacy to prevent subsequent recurrences of CDI (RR = 0.59, 95% CI 0.41–0.85, $p = 0.005$) [McFarland, 2006]. However, due to the limited

number of trials, no meta-analysis was conducted for one probiotic strain.

Several pieces of evidence suggest that *S. boulardii* represents the most effective probiotic that can prevent or, together with other agents, treat antibiotic-associated diarrhea and recurrent CDI [McFarland, 2006] through many mechanisms (Table 2).

Animal models of CDI respond to this yeast and case reports or small case series of patients with recurrent CDI treated with *S. boulardii* showed improvement [McFarland, 2010].

The significant relative reduction in recurrent CDI in adults taking *S. boulardii* compared with controls was evaluated in two RCTs and ranged between 19% and 33.3% [McFarland *et al.* 1994; Surawicz *et al.* 2000]. There are only very limited data from one small observational trial in children suggesting that *S. boulardii* may be effective in CDI [Buts *et al.* 1993]. However, according to guidelines no compelling evidence exists to support routine use of probiotics for prevention or treatment of CDI [Cohen *et al.* 2010] especially since some of these studies did not control the dose or duration of either vancomycin or metronidazole for treatment of CDI [McFarland *et al.* 1994] and since scarce data exist on the use of *S. boulardii* for recurrent CDI in humans.

Acute diarrhea

Two RCTs using *S. boulardii* showed that this probiotic may be effective in treating acute adult diarrhea due to a variety of causes and can significantly lower diarrhea severity score compared with controls [Hochter *et al.* 1990; Mansour-Ghanaei *et al.* 2003]. Unfortunately, since the number of trials in this area is small and the etiologies were different in the two trials, only limited conclusions can be reached.

A recent RCT conducted in 100 hospitalized children showed that *S. boulardii* treatment for 5 days significantly reduces the mean duration of acute diarrhea and frequency of stools, and normalizes stool consistency [Htwe *et al.* 2008]. One RCT regarding the efficacy of *S. boulardii* for the prevention of acute diarrhea involved 100 children with acute watery diarrhea and reported a significant difference in the incidence of diarrheal episodes in the group receiving *S. boulardii* compared with the control group during 2 months follow up [Biloo *et al.* 2006].

A meta-analysis based on 5 RCTs (619 participants) [Biloo *et al.* 2006; Kurugol and Koturoglu, 2005; Villarruel *et al.* 2007] indicated that *S. boulardii* significantly reduces the duration of acute childhood diarrhea and the risk of prolonged diarrhea compared with control [Szajewska *et al.* 2007]. A meta-analysis of seven RCTs (944 participants) showed a reduction in the duration of acute childhood diarrhea by approximately 1 day in those treated with *S. boulardii* compared with placebo [Szajewska and Skorka, 2009]. The absence of blinding as well as other factors such as ambulatory care may explain why *S. boulardii* had no effect in a European RCT [Canani *et al.* 2007]. In summary, the findings from RCTs and guidelines from professional pediatric societies indicate that *S. boulardii* may be an effective adjunct therapy in managing acute gastroenteritis in children [Guarino *et al.* 2008].

Persistent diarrhea

Results from two clinical trials indicate that *S. boulardii* improves outcomes in children with persistent diarrhea [Castaneda *et al.* 1995; Gaon *et al.* 2003]. The relative significant reduction in persistent diarrhea in the *S. boulardii* group compared with controls was approximately 50% [Castaneda *et al.* 1995]. These results indicate that *S. boulardii* is useful in the management of persistent diarrhea in children. However, studies with larger populations are needed to determine whether *S. boulardii* therapy alone is also effective in children with persistent diarrhea.

Enteral nutrition-related diarrhea

Diarrhea is a significant problem in patients on total enteral nutrition (TEN) and may involve changes in intestinal short chain fatty acids (SCFAs) [Schneider *et al.* 2005]. Schneider and colleagues reported a significant increase in SCFAs in 10 enteral-fed patients receiving *S. boulardii* compared with 15 healthy controls [Schneider *et al.* 2005]. *S. boulardii*-induced increase of fecal SCFA concentrations may explain the preventive effects of this yeast on TEN-induced diarrhea [Schneider *et al.* 2005]. In three RCTs the relative significant reduction in enteral nutrition-related diarrhea in the *S. boulardii* group compared with controls ranged between 5% and 8.2% [Bleichner *et al.* 1997; Schlotterer *et al.* 1987; Tempe *et al.* 1983]. More studies are needed to elucidate the mechanisms of how *S. boulardii* can prevent TEN-induced diarrhea.

Traveler's diarrhea

A meta-analysis of 12 RCTs of various probiotics (including *S. boulardii*) for the prevention of traveler's diarrhea found a significant reduction in the risk of traveler's diarrhea when probiotics are used (RR = 0.85, 95% CI 0.79–0.91) [McFarland, 2007]. The relative significant reduction in traveler's diarrhea in the *S. boulardii* group compared with controls in two RCTs ranged between 5% and 11% [Kollaritsch *et al.* 1989, 1993]. These limited numbers of studies indicate that probiotics may be more effective in preventing traveler's diarrhea, rather than treating diarrhea once it becomes symptomatic.

Helicobacter pylori infection

A recent meta-analysis involving 14 RCTs (1671 patients) evaluated the role of probiotics in *H. pylori* eradication [Tong *et al.* 2007]. In patients with *H. pylori* infection, probiotic supplementation improved eradication rates and reduced treatment-related side effects and individual symptoms [Tong *et al.* 2007]. In this meta-analysis, only one RCT evaluated *S. boulardii* and found that it decreased the risk of diarrhea when given concomitantly to patients receiving triple eradication therapy for *H. pylori* [Duman *et al.* 2005]. *S. boulardii* induces morphologic changes in *H. pylori* cells consistent with cellular damage [Vandenplas *et al.* 2009] and was shown to cause reduction in *H. pylori* colonization in infected children by 12% [Gotteland *et al.* 2005]. Of four RCTs testing *S. boulardii* in *H. pylori* infections, two were in children [Gotteland *et al.* 2005; Hurdac *et al.* 2009] and two in adults [Cindoruk *et al.* 2007; Cremonini *et al.* 2002]. Although there was no significant difference in *H. pylori* eradication between the *S. boulardii* and placebo groups, a significantly lower relative rate of AAD (16.1–25%) was observed. In a recent meta-analysis, the *H. pylori* eradication rate in the triple therapy group was 71% and increased significantly to 80% with *S. boulardii* supplementation [Szajewska *et al.* 2010]. Thus, *S. boulardii* may not be effective in eradicating *H. pylori* itself, but it is effective in reducing the side effects of the standard triple therapy.

Clinical efficacy of *Saccharomyces boulardii* as a probiotic in chronic diseases

S. boulardii has been tested for clinical efficacy in several types of chronic diseases including Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), parasitic infections and human immunodeficiency virus (HIV)-related diarrhea.

Crohn's disease

Recently, the use of probiotics for maintaining remission from active disease in patients with Crohn's disease was given a 'C' recommendation rating level by a panel of experts evaluating the efficacy of the supplements, mostly due to a scarcity of data [Floch *et al.* 2008]. In a small pilot study of 31 patients with Crohn's disease in remission all patients continued their maintenance medications and were randomized to either *S. boulardii* for 3 months or placebo [Garcia *et al.* 2008]. Those treated with *S. boulardii* were found to have a significant reduction in colonic permeability compared with those given placebo, thus reducing the risk of bacterial translocation in these patients [Garcia *et al.* 2008]. Two RCTs tested *S. boulardii* for patients with Crohn's disease [Guslandi *et al.* 2000; Plein and Hotz, 1993]. In a small randomized study of 20 patients with Crohn's disease all patients continued their maintenance medications and were randomized to either *S. boulardii* for 7 weeks or placebo. Patients treated with *S. boulardii* were significantly improved compared with the placebo group [Plein and Hotz, 1993]. Finally, in a study of 32 patients with Crohn's disease who were in remission, significantly fewer patients treated with *S. boulardii* (6%) relapsed than the control group (38%) [Guslandi *et al.* 2000]. Further studies to establish the efficacy of *S. boulardii* in treatment of Crohn's disease are needed.

Ulcerative colitis

Probiotics have been used as an adjunct treatment in an attempt to induce remission in patients with active ulcerative colitis flares [Cain and Karpa, 2011]. In a small pilot study of 25 adults with mild to moderate ulcerative colitis that were treated with a combination of mesalazine and *S. boulardii* for 4 weeks, most (68%) of the patients responded to the probiotic treatment [Guslandi *et al.* 2003]. This pilot study had a promising result, but the implications were uncertain as patients were treated for only a short time, were not followed up for subsequent disease flare ups, and no control group was included. In a small pilot study of 6 patients with ulcerative colitis, a therapeutic regimen including *S. boulardii* and rifaximin for 3 months seemed effective in preventing early flare ups of ulcerative colitis [Guslandi, 2010]. Further controlled studies on a larger number of patients treated for longer periods with this probiotic agent are warranted. Overall, based upon current consensus, the level of evidence for use of probiotics

either to maintain remission or induce remission of ulcerative colitis symptoms is presently limited to a 'C' rating [Floch *et al.* 2008].

Irritable bowel syndrome

Recent evidence suggests a role of the microflora in IBS pathogenesis [Parkes *et al.* 2008]. A meta-analysis of 20 RCTs including 1404 subjects found a pooled RR for improvement in global IBS symptoms in 14 probiotic treatment arms (RR = 0.77, 95% CI 0.62–0.94) [McFarland and Dublin, 2008]. In a double-blind trial of *S. boulardii* versus placebo in the treatment of IBS patients, the probiotic agent significantly improved the quality of life, but did not improve intestinal symptoms [Choi *et al.* 2011]. These findings are inconsistent with those reported in double-blind, RCTs performed earlier in France [Bennani, 1990; Maupas *et al.* 1983]. Along these lines, a recent retrospective analysis suggested that addition of *S. boulardii* to mebeverine can provide superior results in IBS treatment and that the probiotic agent does exert beneficial effects on the quality of life and IBS symptoms [Guslandi, 2011]. More trials using *S. boulardii* for IBS are required to allow solid conclusions for its use in this condition.

Parasitic infections

Little is known about the efficacy of *S. boulardii* against protozoal infections but this probiotic seems to have a beneficial effect in amebiasis, giardiasis and infection with *Blastocystis hominis*. In adults, co-administration of lyophilized *S. boulardii* with conventional treatment in acute amebic colitis significantly decreased the duration of symptoms and cyst carriage after 4 weeks [Mansour-Ghanaei *et al.* 2003]. A prospective RCT in patients with amebic colitis showed that addition of *S. boulardii* to metronidazole enhanced clearance of cysts and decreased the mean duration of diarrhea, fever and abdominal pain [Dinleyici *et al.* 2009].

In a small clinical study of symptomatic children with *Blastocystis hominis* infection *S. boulardii* had potential beneficial effects in symptoms and number of parasites [Dinleyici *et al.* 2011].

The combination therapy of *S. boulardii* in addition to metronidazole in patients with giardiasis resulted in a disappearance of *Giardia* cysts 2 weeks after start of the treatment in contrast to

17.1% of patients treated with 10 days metronidazole as monotherapy who still had *Giardia lamblia* cysts in the stool [Besirbellioglu *et al.* 2006]. In another clinical trial of 40 children who received tinidazole for giardiasis of 3 or 4 weeks duration, the percentage of children with only one to three bowel movements per day was significantly higher in the *S. boulardii* group compared with the placebo group (65% versus 15%) [Castaneda *et al.* 1995]. However, all of the studies regarding use of *S. boulardii* for treatment of parasitic infections are small and the reported results need to be confirmed by larger studies.

HIV-related diarrhea

Patients with HIV-associated diarrhea seem to be one group that requires a higher than typical dose of *S. boulardii*. In a blinded, placebo-controlled study in 11 HIV-positive patients who had chronic diarrhea, lower doses of *S. boulardii* were not as effective compared with 6 patients who reported that diarrhea was controlled while taking 3 g/day *S. boulardii* after 1 month [Elmer *et al.* 1995]. In a RCT of 35 adult patients with acquired immune deficiency syndrome (AIDS) and chronic diarrhea, 61% of patients given *S. boulardii* had their diarrhea resolved compared with patients on placebo (12%) [Saint-Marc *et al.* 1991]. Further confirmation on whether higher doses of *S. boulardii* may benefit patients with HIV-related diarrhea is needed since this observation is based on very limited data.

Safety of *Saccharomyces boulardii* as a probiotic

Although no adverse effects were observed in any of the clinical trials with *S. boulardii*, the administration of *S. boulardii* is not without risk. A recent systematic review documented that probiotic products such as *S. boulardii*, have been shown to increase the risk of complications in specific patient groups such as immunocompromised subjects [Whelan and Myers, 2010]. *Saccharomyces* fungemia is the most severe complication secondary to administration of the probiotic especially in patients with severe general or intestinal disease who had an indwelling catheter [Hennequin *et al.* 2000].

Up to now, almost 100 cases of *S. boulardii*-associated fungemia have been reported [Vandenplas *et al.* 2009]. The origin of the fungemia is thought to be either a digestive tract translocation or a contamination of the central venous line by the colonized hands of health workers [Hennequin

et al. 2000; Herek *et al.* 2004]. Indeed, the simple act of opening a packet of *S. boulardii* can produce air contamination that may pose environmental risk especially for immunocompromised patients [Hennequin *et al.* 2000]. Once the diagnosis is made, fungemia with *S. boulardii* can effectively be treated with antimycotic medication, although treatment failure with fluconazole has been reported [Burkhardt *et al.* 2005].

A rare gastrointestinal allergic reaction was also recently reported after *S. boulardii* was given to an infant with a prior diagnosis of food protein-induced enterocolitis syndrome [Hwang *et al.* 2009].

Overall, *S. boulardii* is safe for use in otherwise healthy populations and fungemia with *S. boulardii* has not been reported, to the best of the authors' knowledge, in immunocompetent patients. Caution should be taken in patients with risk factors for adverse events (e.g. patients with central venous catheters or increased bacterial translocation) [Venugopalan *et al.* 2010]. Institutional guidelines are needed to address the potential safety issues related to *S. boulardii* use [Venugopalan *et al.* 2010].

Conclusions

Several clinical trials and experimental studies displayed the role of *S. boulardii* as a good biotherapeutic agent allowing to prevent and/or treat several gastrointestinal diseases. *S. boulardii* mediates effects which resemble the protective effects of the normal healthy gut flora. Although the administration of *S. boulardii* can be associated with fungemia, no adverse effects were observed in any of the clinical trials. Caution should be taken in patients with risk factors for adverse events, such as immunocompromised patients. Larger prospective, placebo controlled clinical trials could elucidate the mechanisms of action of the yeast and suggest new therapeutic applications.

Funding

This research received no specific grant from any funding agency in the public, commercial, or non-profit sectors.

Conflict of interest statement

Dr Kelesidis has no conflicts of interest to declare. Dr Pothoulakis was a paid consultant with Merck and Optimer Pharmaceuticals and a paid speaker for the Postgraduate Institute for Medicine

References

- Barc, M.C., Charrin-Sarnel, C., Rochet, V., Bourlioux, F., Sandre, C., Boureau, H., *et al.* (2008) Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of *Saccharomyces boulardii*. *Anaerobe* 14: 229–233.
- Bartlett, J.G. (2002) Clinical practice. Antibiotic-associated diarrhea. *N Engl J Med* 346: 334–339.
- Bennani, A. (1990) Randomised trial of *Saccharomyces boulardii* in the treatment of functional colon disorders. *L'Objectif Medical* 73: 56–61.
- Besirbellioglu, B.A., Ulcay, A., Can, M., Erdem, H., Tanyuksel, M., Avci, I.Y. *et al.* (2006) *Saccharomyces boulardii* and infection due to *Giardia lamblia*. *Scand J Infect Dis* 38: 479–481.
- Biloo, A.G., Memon, M.A., Khaskheli, S.A., Murtaza, G., Iqbal, K., Saeed, S.M. *et al.* (2006) Role of a probiotic (*Saccharomyces boulardii*) in management and prevention of diarrhoea. *World J Gastroenterol* 12: 4557–4560.
- Bisson, J.F., Hidalgo, S., Rozan, P. and Messaoudi, M. (2010) Preventive effects of different probiotic formulations on travelers' diarrhea model in Wistar rats: preventive effects of probiotics on TD. *Dig Dis Sci* 55: 911–919.
- Blehaut, H., Massot, J., Elmer, G.W. and Levy, R.H. (1989) Disposition kinetics of *Saccharomyces boulardii* in man and rat. *Biopharm Drug Dispos* 10: 353–364.
- Bleichner, G., Blehaut, H., Mentec, H. and Moysse, D. (1997) *Saccharomyces boulardii* prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. *Intensive Care Med* 23: 517–523.
- Brandao, R.L., Castro, I.M., Bambilra, E.A., Amaral, S.C., Fietto, L.G., Tropia, M.J. *et al.* (1998) Intracellular signal triggered by cholera toxin in *Saccharomyces boulardii* and *Saccharomyces cerevisiae*. *Appl Environ Microbiol* 64: 564–568.
- Breves, G., Faul, K., Schroder, B., Holst, H., Caspary, W.F. and Stein, J. (2000) Application of the colon-simulation technique for studying the effects of *Saccharomyces boulardii* on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. *Digestion* 61: 193–200.
- Burkhardt, O., Kohnlein, T., Pletz, M. and Welte, T. (2005) *Saccharomyces boulardii* induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. *Scand J Infect Dis* 37: 69–72.
- Buts, J.P. (2009) Twenty-five years of research on *Saccharomyces boulardii* trophic effects: updates and perspectives. *Dig Dis Sci* 54: 15–18.
- Buts, J.P., Bernasconi, P., Vaerman, J.P. and Dive, C. (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with *Saccharomyces boulardii*. *Dig Dis Sci* 35: 251–256.
- Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P. and De, M.R. (1986) Response of human and rat small intestinal mucosa to oral administration of *Saccharomyces boulardii*. *Pediatr Res* 20: 192–196.
- Buts, J.P., Corthier, G. and Delmee, M. (1993) *Saccharomyces boulardii* for Clostridium difficile-associated enteropathies in infants. *J Pediatr Gastroenterol Nutr* 16: 419–425.
- Buts, J.P., De, K.N. and De, R.L. (1994) *Saccharomyces boulardii* enhances rat intestinal enzyme expression by endoluminal release of polyamines. *Pediatr Res* 36: 522–527.
- Buts, J.P., De, K.N., Marandi, S., Hermans, D., Sokal, E.M., Chae, Y.H. *et al.* (1999) *Saccharomyces boulardii* upgrades cellular adaptation after proximal enterectomy in rats. *Gut* 45: 89–96.
- Buts, J.P., De, K.N., Stilmant, C., Sokal, E. and Marandi, S. (2002) *Saccharomyces boulardii* enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. *Pediatr Res* 51: 528–534.
- Buts, J.P., Dekeyser, N., Stilmant, C., Delem, E., Smets, F. and Sokal, E. (2006) *Saccharomyces boulardii* produces in rat small intestine a novel protein phosphatase that inhibits *Escherichia coli* endotoxin by dephosphorylation. *Pediatr Res* 60: 24–29.
- Buts, J.P., Durantou, B., De, K.N., Sokal, E.M., Maernhout, A.S., Raul, F. *et al.* (1998) Premature stimulation of rat sucrase-isomaltase (SI) by exogenous insulin and the analog B-Asp10 is regulated by a receptor-mediated signal triggering SI gene transcription. *Pediatr Res* 43: 585–591.
- Caetano, J.A., Parames, M.T., Babo, M.J., Santos, A., Ferreira, A.B., Freitas, A.A. *et al.* (1986) Immunopharmacological effects of *Saccharomyces boulardii* in healthy human volunteers. *Int J Immunopharmacol* 8: 245–259.
- Cain, A.M. and Karpa, K.D. (2011) Clinical utility of probiotics in inflammatory bowel disease. *Altern Ther Health Med* 17: 72–79.
- Can, M., Besirbellioglu, B.A., Avci, I.Y., Beker, C.M. and Pahsa, A. (2006) Prophylactic *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea: a prospective study. *Med Sci Monit* 12: I19–I22.
- Canani, R.B., Cirillo, P., Terrin, G., Cesarano, L., Spagnuolo, M.I., De, V.A. *et al.* (2007) Probiotics for treatment of acute diarrhoea in children: randomised

- clinical trial of five different preparations. *BMJ* 335: 340.
- Canil, C., Rosenshine, I., Ruschkowski, S., Donnenberg, M.S., Kaper, J.B. and Finlay, B.B. (1993) Enteropathogenic *Escherichia coli* decreases the transepithelial electrical resistance of polarized epithelial monolayers. *Infect Immun* 61: 2755–2762.
- Canonici, A., Siret, C., Pellegrino, E., Pontier-Bres, R., Pouyet, L., Montero, M.P. *et al.* (2011) *Saccharomyces boulardii* improves intestinal cell restitution through activation of the alpha2beta1 integrin collagen receptor. *PLoS One* 6: e18427.
- Castagliuolo, I., LaMont, J.T., Nikulasson, S.T. and Pothoulakis, C. (1996) *Saccharomyces boulardii* protease inhibits *Clostridium difficile* toxin A effects in the rat ileum. *Infect Immun* 64: 5225–5232.
- Castagliuolo, I., Riegler, M.F., Valenick, L., LaMont, J.T. and Pothoulakis, C. (1999) *Saccharomyces boulardii* protease inhibits the effects of *Clostridium difficile* toxins A and B in human colonic mucosa. *Infect Immun* 67: 302–307.
- Castaneda, C., Garcia, E., Santa Cruz, M., Fernandez, M. and Monterrey, P. (1995) Effects of *Saccharomyces boulardii* in children with chronic diarrhea, especially cases due to giardiasis. *Rev Mex Pueric Pediatr* 2: 12–16.
- Castex, F., Corthier, G., Jouvert, S., Elmer, G.W., Lucas, F. and Bastide, M. (1990) Prevention of *Clostridium difficile*-induced experimental pseudomembranous colitis by *Saccharomyces boulardii*: a scanning electron microscopic and microbiological study. *J Gen Microbiol* 136: 1085–1089.
- Chen, X., Kokkotou, E.G., Mustafa, N., Bhaskar, K.R., Sougioultzis, S., O'Brien, M. *et al.* (2006) *Saccharomyces boulardii* inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against *Clostridium difficile* toxin A-induced enteritis. *J Biol Chem* 281: 24449–24454.
- Choi, C.H., Jo, S.Y., Park, H.J., Chang, S.K., Byeon, J.S. and Myung, S.J. (2011) A randomized, double-blind, placebo-controlled multicenter trial of *Saccharomyces boulardii* in irritable bowel syndrome: effect on quality of life. *J Clin Gastroenterol*, in press.
- Cindoruk, M., Erkan, G., Karakan, T., Dursun, A. and Unal, S. (2007) Efficacy and safety of *Saccharomyces boulardii* in the 14-day triple anti-*Helicobacter pylori* therapy: a prospective randomized placebo-controlled double-blind study. *Helicobacter* 12: 309–316.
- Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C. *et al.* (2010) Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 31: 431–455.
- Cremonini, F., Di, C.S., Covino, M., Armuzzi, A., Gabrielli, M., Santarelli, L. *et al.* (2002) Effect of different probiotic preparations on anti-*Helicobacter pylori* therapy-related side effects: a parallel group, triple blind, placebo-controlled study. *Am J Gastroenterol* 97: 2744–2749.
- Czerucka, D., Dahan, S., Mograbi, B., Rossi, B. and Rampal, P. (2000) *Saccharomyces boulardii* preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic *Escherichia coli*-infected T84 cells. *Infect Immun* 68: 5998–6004.
- Czerucka, D., Piche, T. and Rampal, P. (2007) Review article: yeast as probiotics — *Saccharomyces boulardii*. *Aliment Pharmacol Ther* 26: 767–778.
- Czerucka, D. and Rampal, P. (2002) Experimental effects of *Saccharomyces boulardii* on diarrheal pathogens. *Microbes Infect* 4: 733–739.
- Czerucka, D., Roux, I. and Rampal, P. (1994) *Saccharomyces boulardii* inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. *Gastroenterology* 106: 65–72.
- Dahan, S., Busuttil, V., Imbert, V., Peyron, J.F., Rampal, P. and Czerucka, D. (2002) Enterohemorrhagic *Escherichia coli* infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in T84 cells. *Infect Immun* 70: 2304–2310.
- Dahan, S., Dalmaso, G., Imbert, V., Peyron, J.F., Rampal, P. and Czerucka, D. (2003) *Saccharomyces boulardii* interferes with enterohemorrhagic *Escherichia coli*-induced signaling pathways in T84 cells. *Infect Immun* 71:766–773.
- Dalmaso, G., Cottrez, F., Imbert, V., Lagadec, P., Peyron, J.F., Rampal, P. *et al.* (2006a) *Saccharomyces boulardii* inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. *Gastroenterology* 131: 1812–1825.
- Dalmaso, G., Loubat, A., Dahan, S., Calle, G., Rampal, P. and Czerucka, D. (2006b) *Saccharomyces boulardii* prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. *Res Microbiol* 157: 456–465.
- Dinleyici, E.C., Eren, M., Dogan, N., Reyhanioglu, S., Yargic, Z.A. and Vandenplas, Y. (2011) Clinical efficacy of *Saccharomyces boulardii* or metronidazole in symptomatic children with *Blastocystis hominis* infection. *Parasitol Res* 108: 541–545.
- Dinleyici, E.C., Eren, M., Yargic, Z.A., Dogan, N. and Vandenplas, Y. (2009) Clinical efficacy of *Saccharomyces boulardii* and metronidazole compared

- with metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. *Am J Trop Med Hyg* 80: 953–955.
- Duman, D.G., Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., Istan, F. *et al.* (2005) Efficacy and safety of *Saccharomyces boulardii* in prevention of antibiotic-associated diarrhoea due to *Helicobacter pylori* eradication. *Eur J Gastroenterol Hepatol* 17: 1357–1361.
- Elmer, G.W. and Corthier, G. (1991) Modulation of *Clostridium difficile* induced mortality as a function of the dose and the viability of the *Saccharomyces boulardii* used as a preventative agent in gnotobiotic mice. *Can J Microbiol* 37: 315–317.
- Elmer, G.W., Martin, S.W., Horner, K.L., McFarland, L.V. and Levy, R.H. (1999a) Survival of *Saccharomyces boulardii* in the rat gastrointestinal tract and effects of dietary fiber. *Microb Ecology Health Dis* 11: 29–34.
- Elmer, G.W., McFarland, L.V., Surawicz, C.M., Danko, L. and Greenberg, R.N. (1999b) Behaviour of *Saccharomyces boulardii* in recurrent *Clostridium difficile* disease patients. *Aliment Pharmacol Ther* 13: 1663–1668.
- Elmer, G.W., Moyer, K.A., Vega, R., Surawicz, C.M., Collier, A.C., Hooton, T.M. *et al.* (1995) Evaluation of *Saccharomyces boulardii* for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. *Microb Ther* 25: 23–31.
- Fidan, I., Kalkanci, A., Yesilyurt, E., Yalcin, B., Erdal, B., Kustimur, S. *et al.* (2009) Effects of *Saccharomyces boulardii* on cytokine secretion from intraepithelial lymphocytes infected by *Escherichia coli* and *Candida albicans*. *Mycoses* 52: 29–34.
- Floch, M.H., Walker, W.A., Guandalini, S., Hibberd, P., Gorbach, S., Surawicz, C. *et al.* (2008) Recommendations for probiotic use—2008. *J Clin Gastroenterol* 42(Suppl. 2): S104–S108.
- Gaon, D., Garcia, H. and Winter, L. (2003) Effect of *Lactobacillus* strains and *Saccharomyces boulardii* on persistent diarrhea in children. *Medicina (B Aires)* 63: 293–298.
- Garcia, V.E., De Lourdes De Abreu, F., Oswaldo Da Gama, T.H., Guerra, P.A., Carolina Carneiro, A.A., Paiva, M.F. *et al.* (2008) Influence of *Saccharomyces boulardii* on the intestinal permeability of patients with Crohn's disease in remission. *Scand J Gastroenterol* 43: 842–848.
- Gareau, M.G., Sherman, P.M. and Walker, W.A. (2010) Probiotics and the gut microbiota in intestinal health and disease. *Nat Rev Gastroenterol Hepatol* 7: 503–514.
- Gedek, B.R. (1999a) Adherence of *Escherichia coli* serogroup O 157 and the *Salmonella typhimurium* mutant DT 104 to the surface of *Saccharomyces boulardii*. *Mycoses* 42: 261–264.
- Gedek, B.R. (1999b) Adherence of *Escherichia coli* serogroup O 157 and the *Salmonella typhimurium* mutant DT 104 to the surface of *Saccharomyces boulardii*. *Mycoses* 42: 261–264.
- Generoso, S.V., Viana, M.L., Santos, R.G., Arantes, R.M., Martins, F.S., Nicoli, J.R. *et al.* (2011) Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed *Saccharomyces boulardii*. *Eur J Nutr* 50: 261–269.
- Geyik, M.F., Aldemir, M., Hosoglu, S., Ayaz, C., Satilmis, S., Buyukbayram, H. *et al.* (2006) The effects of *Saccharomyces boulardii* on bacterial translocation in rats with obstructive jaundice. *Ann R Coll Surg Engl* 88: 176–180.
- Girard, P., Pansart, Y. and Gillardin, J.M. (2005) Inducible nitric oxide synthase involvement in the mechanism of action of *Saccharomyces boulardii* in castor oil-induced diarrhoea in rats. *Nitric Oxide* 13: 163–169.
- Gorbach, S.L. (2000) Probiotics and gastrointestinal health. *Am J Gastroenterol* 95: S2–S4.
- Gotteland, M., Poliak, L., Cruchet, S. and Brunser, O. (2005) Effect of regular ingestion of *Saccharomyces boulardii* plus inulin or *Lactobacillus acidophilus* LB in children colonized by *Helicobacter pylori*. *Acta Paediatr* 94: 1747–1751.
- Graff, S., Chaumeil, J.C., Boy, P., Lai-Kuen, R. and Charrueau, C. (2008a) Formulations for protecting the probiotic *Saccharomyces boulardii* from degradation in acidic condition. *Biol Pharm Bull* 31: 266–272.
- Graff, S., Chaumeil, J.C., Boy, P., Lai-Kuen, R. and Charrueau, C. (2008b) Influence of pH conditions on the viability of *Saccharomyces boulardii* yeast. *J Gen Appl Microbiol* 54: 221–227.
- Guarino, A., Albano, F., Ashkenazi, S., Gendrel, D., Hoekstra, J.H., Shamir, R. *et al.* (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. *J Pediatr Gastroenterol Nutr* 46(Suppl. 2): S81–S122.
- Guslandi, M. (2010) *Saccharomyces boulardii* plus rifaximin in mesalamine-intolerant ulcerative colitis. *J Clin Gastroenterol* 44:385.
- Guslandi, M. (2011) Treatment of irritable bowel syndrome with *Saccharomyces boulardii*. *J Clin Gastroenterol*, in press.

- Guslandi, M., Giollo, P. and Testoni, P.A. (2003) A pilot trial of *Saccharomyces boulardii* in ulcerative colitis. *Eur J Gastroenterol Hepatol* 15: 697–698.
- Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, P.A. (2000) *Saccharomyces boulardii* in maintenance treatment of Crohn's disease. *Dig Dis Sci* 45: 1462–1464.
- Hennequin, C., Kauffmann-Lacroix, C., Jobert, A., Viard, J.P., Ricour, C., Jacquemin, J.L. et al. (2000) Possible role of catheters in *Saccharomyces boulardii* fungemia. *Eur J Clin Microbiol Infect Dis* 19: 16–20.
- Herek, O., Kara, I.G. and Kaleli, I. (2004) Effects of antibiotics and *Saccharomyces boulardii* on bacterial translocation in burn injury. *Surg Today* 34: 256–260.
- Hochter, W., Chase, D. and Hagenhoff, G. (1990) *Saccharomyces boulardii* in acute adult diarrhea: efficacy and tolerability of treatment. *Munch Med Wschr* 132: 188–192.
- Htwe, K., Yee, K.S., Tin, M. and Vandenplas, Y. (2008) Effect of *Saccharomyces boulardii* in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. *Am J Trop Med Hyg* 78: 214–216.
- Hurdac, V., Plesca, D., Dragomir, D., Sajin, M. and Vandenplas, Y. (2009) A randomized, open trial evaluating the effect of *Saccharomyces boulardii* on the eradication rate of *Helicobacter pylori* infection in children. *Acta Paediatr* 98: 127–131.
- Hwang, J.B., Kang, K.J., Kang, Y.N. and Kim, A.S. (2009) Probiotic gastrointestinal allergic reaction caused by *Saccharomyces boulardii*. *Ann Allergy Asthma Immunol* 103: 87–88.
- Im, E. and Pothoulakis, C. (2010) [Recent advances in *Saccharomyces boulardii* research]. *Gastroenterol Clin Biol* 34(Suppl. 1): S62–S70.
- Jahn, H.U., Ullrich, R., Schneider, T., Liehr, R.M., Schieferdecker, H.L., Holst, H. et al. (1996) Immunological and trophical effects of *Saccharomyces boulardii* on the small intestine in healthy human volunteers. *Digestion* 57: 95–104.
- Kajander, K., Myllyluoma, E., Rajilic-Stojanovic, M., Kyronpalo, S., Rasmussen, M., Jarvenpaa, S. et al. (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. *Aliment Pharmacol Ther* 27: 48–57.
- Klein, S.M., Elmer, G.W., McFarland, L.V., Surawicz, C.M. and Levy, R.H. (1993) Recovery and elimination of the biotherapeutic agent, *Saccharomyces boulardii*, in healthy human volunteers. *Pharm Res* 10: 1615–1619.
- Kollaritsch, H., Holst, H., Grobara, P. and Wiedermann, G. (1993) [Prevention of traveler's diarrhea with *Saccharomyces boulardii*. Results of a placebo controlled double-blind study]. *Fortschr Med* 111: 152–156.
- Kollaritsch, H., Kremsner, P., Wiedermann, G. and Scheiner, O. (1989) Prevention of traveller's diarrhea: comparison of different non-antibiotic preparations. *Travel Med Internat* 7: 9–18.
- Kotowska, M., Albrecht, P. and Szajewska, H. (2005) *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. *Aliment Pharmacol Ther* 21: 583–590.
- Kurugol, Z. and Koturoglu, G. (2005) Effects of *Saccharomyces boulardii* in children with acute diarrhoea. *Acta Paediatr* 94: 44–47.
- Kyne, L., Warny, M., Qamar, A. and Kelly, C.P. (2001) Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *Lancet* 357: 189–193.
- Lee, S.K., Kim, H.J., Chi, S.G., Jang, J.Y., Nam, K.D., Kim, N.H. et al. (2005) [*Saccharomyces boulardii* activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells]. *Korean J Gastroenterol* 45: 328–334.
- Lee, S.K., Kim, Y.W., Chi, S.G., Joo, Y.S. and Kim, H.J. (2009) The effect of *Saccharomyces boulardii* on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. *Dig Dis Sci* 54: 255–263.
- Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K. and Shafaghi, A. (2003) Efficacy of *Saccharomyces boulardii* with antibiotics in acute amoebiasis. *World J Gastroenterol* 9: 1832–1833.
- Marcobal, A., Underwood, M.A. and Mills, D.A. (2008) Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. *J Pediatr Gastroenterol Nutr* 46: 608–611.
- Martins, F.S., Nardi, R.M., Arantes, R.M., Rosa, C.A., Neves, M.J. and Nicoli, J.R. (2005) Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. *J Gen Appl Microbiol* 51: 83–92.
- Martins, F.S., Veloso, L.C., Arantes, R.M. and Nicoli, J.R. (2009) Effects of yeast probiotic formulation on viability, revival and protection against infection with *Salmonella enterica* ssp. enterica serovar Typhimurium in mice. *Lett Appl Microbiol* 49: 738–744.
- Masco, L., Huys, G., De, B.E., Temmerman, R. and Swings, J. (2005) Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. *Int J Food Microbiol* 102: 221–230.

- Maupas, J.L., Champemont, P. and Delforge, M. (1983) Treatment of irritable bowel syndrome with *Saccharomyces boulardii*: a double-blind, placebo-controlled study. *Med Chir Dig* 12: 77–79.
- McFarland, L.V. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol* 101: 812–822.
- McFarland, L.V. (2007) Meta-analysis of probiotics for the prevention of traveler's diarrhea. *Travel Med Infect Dis* 5: 97–105.
- McFarland, L.V. (2009) Unraveling the causes of negative studies: a case of *S. boulardii* for the prevention of antibiotic-associated diarrhea. *Rev Med Chil* 137: 719–720.
- McFarland, L.V. (2010) Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. *World J Gastroenterol* 16: 2202–2222.
- McFarland, L.V. and Dublin, S. (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol* 14: 2650–2661.
- McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A. et al. (1994) A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 271: 1913–1918.
- Mumy, K.L., Chen, X., Kelly, C.P. and McCormick, B.A. (2008) *Saccharomyces boulardii* interferes with *Shigella* pathogenesis by postinvasion signaling events. *Am J Physiol Gastrointest Liver Physiol* 294: G599–G609.
- Pant, N., Marcotte, H., Brussow, H., Svensson, L. and Hammarstrom, L. (2007) Effective prophylaxis against rotavirus diarrhea using a combination of *Lactobacillus rhamnosus* GG and antibodies. *BMC Microbiol* 7: 86.
- Parkes, G.C., Brostoff, J., Whelan, K. and Sanderson, J.D. (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. *Am J Gastroenterol* 103: 1557–1567.
- Plein, K. and Hotz, J. (1993) Therapeutic effects of *Saccharomyces boulardii* on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea—a pilot study. *Z Gastroenterol* 31: 129–134.
- Pothoulakis, C. (2009) Review article: anti-inflammatory mechanisms of action of *Saccharomyces boulardii*. *Aliment Pharmacol Ther* 30: 826–833.
- Pothoulakis, C., Kelly, C.P., Joshi, M.A., Gao, N., O'Keane, C.J., Castagliuolo, I. et al. (1993) *Saccharomyces boulardii* inhibits *Clostridium difficile* toxin A binding and enterotoxicity in rat ileum. *Gastroenterology* 104: 1108–1115.
- Qamar, A., Aboudola, S., Warny, M., Michetti, P., Pothoulakis, C., LaMont, J.T. et al. (2001) *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to *Clostridium difficile* toxin A in mice. *Infect Immun* 69: 2762–2765.
- Rigotherier, M.C., Maccario, J. and Gayral, P. (1994) Inhibitory activity of *Saccharomyces* yeasts on the adhesion of *Entamoeba histolytica* trophozoites to human erythrocytes *in vitro*. *Parasitol Res* 80: 10–15.
- Rodrigues, A.C., Cara, D.C., Fretez, S.H., Cunha, F.Q., Vieira, E.C., Nicoli, J.R. et al. (2000) *Saccharomyces boulardii* stimulates sIgA production and the phagocytic system of gnotobiotic mice. *J Appl Microbiol* 89: 404–414.
- Rodrigues, A.C., Nardi, R.M., Bambirra, E.A., Vieira, E.C. and Nicoli, J.R. (1996) Effect of *Saccharomyces boulardii* against experimental oral infection with *Salmonella typhimurium* and *Shigella flexneri* in conventional and gnotobiotic mice. *J Appl Bacteriol* 81: 251–256.
- Saint-Marc, T., Rossello-Prats, L. and Touraine, J.L. (1991) [Efficacy of *Saccharomyces boulardii* in the treatment of diarrhea in AIDS]. *Ann Med Interne (Paris)* 142: 64–65.
- Schlotterer, M., Bernasconi, P., Lebreton, F. and Wassermann, D. (1987) Value of *Saccharomyces boulardii* in the digestive acceptability of continuous-flow enteral nutrition in burnt patients. *Nutr Clin Metabol* 1: 31–34.
- Schneider, S.M., Girard-Pipau, F., Filippi, J., Hebuterne, X., Moyses, D., Hinojosa, G.C. et al. (2005) Effects of *Saccharomyces boulardii* on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. *World J Gastroenterol* 11: 6165–6169.
- Schwenzer, V.B. (1998) *Saccharomyces boulardii*. *Deutsche Apotheker Zeitung* 138: 75–77.
- Sezer, A., Usta, U. and Cicin, I. (2009) The effect of *Saccharomyces boulardii* on reducing irinotecan-induced intestinal mucositis and diarrhea. *Med Oncol* 26: 350–357.
- Sougioultzis, S., Simeonidis, S., Bhaskar, K.R., Chen, X., Anton, P.M., Keates, S. et al. (2006) *Saccharomyces boulardii* produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. *Biochem Biophys Res Commun* 343: 69–76.
- Surawicz, C.M., McFarland, L.V., Greenberg, R.N., Rubin, M., Fekety, R., Mulligan, M.E. et al. (2000) The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis* 31: 1012–1017.

- Swidsinski, A., Loening-Baucke, V., Verstraelen, H., Osowska, S. and Doerffel, Y. (2008) Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. *Gastroenterology* 135: 568–579.
- Szajewska, H., Horvath, A. and Piwowarczyk, A. (2010) Meta-analysis: the effects of *Saccharomyces boulardii* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment. *Aliment Pharmacol Ther* 32: 1069–1079.
- Szajewska, H. and Mrukowicz, J. (2005) Meta-analysis: non-pathogenic yeast *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 22: 365–372.
- Szajewska, H., Setty, M., Mrukowicz, J. and Guandalini, S. (2006) Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. *J Pediatr Gastroenterol Nutr* 42: 454–475.
- Szajewska, H. and Skorka, A. (2009) *Saccharomyces boulardii* for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. *Aliment Pharmacol Ther* 30: 960–961.
- Szajewska, H., Skorka, A. and Dylag, M. (2007) Meta-analysis: *Saccharomyces boulardii* for treating acute diarrhoea in children. *Aliment Pharmacol Ther* 25: 257–264.
- Tasteyre, A., Barc, M.C., Karjalainen, T., Bourlioux, P. and Collignon, A. (2002) Inhibition of in vitro cell adherence of *Clostridium difficile* by *Saccharomyces boulardii*. *Microb Pathog* 32: 219–225.
- Tempe, J.D., Steidel, A.L., Blehaut, H., Hasselmann, M., Lutun, P. and Maurier, F. (1983) [Prevention of diarrhea administering *Saccharomyces boulardii* during continuous enteral feeding]. *Sem Hop* 59: 1409–1412.
- Thomas, S., Przesdzing, I., Metzke, D., Schmitz, J., Radbruch, A. and Baumgart, D.C. (2009) *Saccharomyces boulardii* inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. *Clin Exp Immunol* 156: 78–87.
- Tong, J.L., Ran, Z.H., Shen, J., Zhang, C.X. and Xiao, S.D. (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther* 25: 155–168.
- Toothaker, R.D. and Elmer, G.W. (1984) Prevention of clindamycin-induced mortality in hamsters by *Saccharomyces boulardii*. *Antimicrob Agents Chemother* 26: 552–556.
- Vandenplas, Y., Brunser, O. and Szajewska, H. (2009) *Saccharomyces boulardii* in childhood. *Eur J Pediatr* 168: 253–265.
- Venugopalan, V., Shriner, K.A. and Wong-Beringer, A. (2010) Regulatory oversight and safety of probiotic use. *Emerg Infect Dis* 16: 1661–1665.
- Vidon, N., Huchet, B. and Rambaud, J.C. (1986) [Influence of *Saccharomyces boulardii* on jejunal secretion in rats induced by cholera toxin]. *Gastroenterol Clin Biol* 10: 13–16.
- Villarruel, G., Rubio, D.M., Lopez, F., Cintioni, J., Gurevech, R., Romero, G. et al. (2007) *Saccharomyces boulardii* in acute childhood diarrhoea: a randomized, placebo-controlled study. *Acta Paediatr* 96: 538–541.
- Weese, J.S. (2003) Evaluation of deficiencies in labeling of commercial probiotics. *Can Vet J* 44: 982–983.
- Whelan, K. and Myers, C.E. (2010) Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. *Am J Clin Nutr* 91: 687–703.
- Wu, X., Vallance, B.A., Boyer, L., Bergstrom, K.S., Walker, J., Madsen, K. et al. (2008) *Saccharomyces boulardii* ameliorates *Citrobacter rodentium*-induced colitis through actions on bacterial virulence factors. *Am J Physiol Gastrointest Liver Physiol* 294: G295–G306.
- Zanello, G., Meurens, F., Berri, M. and Salmon, H. (2009) *Saccharomyces boulardii* effects on gastrointestinal diseases. *Curr Issues Mol Biol* 11: 47–58.